Headquartered in Hyderabad, India, Granules offers collaborative and strategic partnership to global pharmaceutical leaders by producing best quality API, PFI and FD through manufacturing …

We strive to provide access to safe, effective and affordable medicines to the people who need them. Here is how our key strengths help us achieve our objective.

In the API sector, Granules is among the largest manufacturers of first line of defence products (paracetamol, metformin, ibuprofen, guaifenesin & methocarbamol).

This acquisition strengthens Granules’ portfolio and opens up growth opportunities in the integrated Generics space in coming years. Granules will provide finished dosages of the new APIs in order to …

Hyderabad, December 1, 2025: Granules India Limited today inaugurated two advanced Centres of Excellence at the Technology Research Park of IIT Hyderabad: the Ascelis Center of Excellence for …

This achievement highlights Granules’ expanding capabilities in complex formulation development and regulatory execution. It reinforces the Company’s ability to identify, develop, and progress technically …

Over the past four decades, Granules India has emerged as a high-growth, vertically integrated pharmaceutical company with consistent performance and a growing global footprint.

Granules India is a vertically integrated, high-growth pharmaceutical product manufacturing company based in Hyderabad, India. We manufacture high-quality API, FD, PFI and Speciality Products with a …

Granules in the news Featured in this section are important public updates pertaining to our products, performance and business, along with print coverage in the media.

Our Gagillapur unit is one of the largest single unit manufacturing site for PFIs and Finished Dosages which we are further adding to by increasing technology based capacities. In an effort towards …